Cargando…
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/ https://www.ncbi.nlm.nih.gov/pubmed/33879600 http://dx.doi.org/10.1136/jitc-2021-002460 |
_version_ | 1783681648936615936 |
---|---|
author | Beyranvand Nejad, Elham Labrie, Camilla van Elsas, Marit J Kleinovink, Jan Willem Mittrücker, Hans-Willi Franken, Kees L M C Heink, Sylvia Korn, Thomas Arens, Ramon van Hall, Thorbald van der Burg, Sjoerd H |
author_facet | Beyranvand Nejad, Elham Labrie, Camilla van Elsas, Marit J Kleinovink, Jan Willem Mittrücker, Hans-Willi Franken, Kees L M C Heink, Sylvia Korn, Thomas Arens, Ramon van Hall, Thorbald van der Burg, Sjoerd H |
author_sort | Beyranvand Nejad, Elham |
collection | PubMed |
description | BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.control. Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6ra(fl/fl)×LysM(cre+) mice. RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8(+) T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8(+) T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6ra(fl/fl)×LysM(cre+) but not cre-negative control mice, while no differences in the vaccine-induced CD8(+) T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages. CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections. |
format | Online Article Text |
id | pubmed-8061866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80618662021-05-11 IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors Beyranvand Nejad, Elham Labrie, Camilla van Elsas, Marit J Kleinovink, Jan Willem Mittrücker, Hans-Willi Franken, Kees L M C Heink, Sylvia Korn, Thomas Arens, Ramon van Hall, Thorbald van der Burg, Sjoerd H J Immunother Cancer Basic Tumor Immunology BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1.control. Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6ra(fl/fl)×LysM(cre+) mice. RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8(+) T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8(+) T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6ra(fl/fl)×LysM(cre+) but not cre-negative control mice, while no differences in the vaccine-induced CD8(+) T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages. CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections. BMJ Publishing Group 2021-04-20 /pmc/articles/PMC8061866/ /pubmed/33879600 http://dx.doi.org/10.1136/jitc-2021-002460 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Basic Tumor Immunology Beyranvand Nejad, Elham Labrie, Camilla van Elsas, Marit J Kleinovink, Jan Willem Mittrücker, Hans-Willi Franken, Kees L M C Heink, Sylvia Korn, Thomas Arens, Ramon van Hall, Thorbald van der Burg, Sjoerd H IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title | IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title_full | IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title_fullStr | IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title_full_unstemmed | IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title_short | IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
title_sort | il-6 signaling in macrophages is required for immunotherapy-driven regression of tumors |
topic | Basic Tumor Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/ https://www.ncbi.nlm.nih.gov/pubmed/33879600 http://dx.doi.org/10.1136/jitc-2021-002460 |
work_keys_str_mv | AT beyranvandnejadelham il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT labriecamilla il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT vanelsasmaritj il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT kleinovinkjanwillem il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT mittruckerhanswilli il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT frankenkeeslmc il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT heinksylvia il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT kornthomas il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT arensramon il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT vanhallthorbald il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors AT vanderburgsjoerdh il6signalinginmacrophagesisrequiredforimmunotherapydrivenregressionoftumors |